Dorzolamide

Dorzolamide, sold under the brand name Trusopt among others, is medications used to treat high pressure inside the eye including glaucoma.[1] It is used as an eye drop.[1] Effects begin within three hours and lasts for at least eight hours.[1] It is also available as the combination dorzolamide/timolol.[1]

Dorzolamide
Clinical data
Trade namesTrusopt, others
AHFS/Drugs.comMonograph
MedlinePlusa602022
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Topical (eye drops)
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Protein binding~33%
    Elimination half-life4 months
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC10H16N2O4S3
    Molar mass324.43 g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Common side effects include eye discomfort, eye redness, taste changes, and blurry vision.[1] Serious side effects include Steven Johnson syndrome.[1] Those allergic to sulfonamides may be allergic to dorzolamide.[1][2] Use is not recommended in pregnancy or breastfeeding.[2] It is a carbonic anhydrase inhibitor and works by decreasing the production of aqueous humour.[1]

    Dorzolamide was approved for medical use in the United States in 1994.[1] It is available as a generic medication.[2] A 5 milliliter bottle in the United Kingdom costs the NHS less than £2 as of 2019.[2] In the United States the wholesale cost of this amount is about US$7.10.[3] In 2017, it was the 281st most commonly prescribed medication in the United States, with more than one million prescriptions.[4][5]

    Medical uses

    Dorzolamide hydrochloride is used to lower excessive intraocular pressure in open-angle glaucoma and ocular hypertension.

    Side effects

    Ocular stinging, burning, itching and bitter taste.[6] It causes shallowing of the anterior chamber and leads to transient myopia.

    Pharmacodynamics

    It lowers IOP by about 20%.[6] Carbonic Anhydrase can convert H2CO3 into HCO3 (bicarbonate) and H+. The H+ is then exchanged for sodium (Na) which allows you to make aqueous humor. By blocking carbonic anhydrase, the Na/H exchanger can't work, which will decrease Na in the cell and prevent aqueous humor production.

    History

    This drug, developed by Merck, was the first drug in human therapy (market introduction 1995) that resulted from structure-based drug design. It was developed to circumvent the systemic side effects of acetazolamide which has to be taken orally.[6]

    gollark: Yep!
    gollark: I have no hatchling slots right now, though.
    gollark: I think you forgot.
    gollark: Maybe I should trade off ARBITRARYPREFIX coppers.
    gollark: Also, whenever someone mentions messiness like inbreeding, I am required to show this:https://dragcave.net/lineage/XGkXi

    References
    1. "Dorzolamide Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.
    2. British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1148. ISBN 9780857113382.
    3. "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
    4. "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
    5. "Dorzolamide Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
    6. KD Tripari MD. Essentials of Medical Pharmacology (5th ed.). Jaypee Brothers Medical Publishers(P) Ltd. p. 88. ISBN 81-8061-187-6.

    Further reading
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.